Terms: = Breast cancer AND PSA AND Staging
16 results:
1. Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
Hou Y; Jiang KW; Wang LL; Zhi R; Bao ML; Li Q; Zhang J; Qu JR; Zhu FP; Zhang YD
Br J Cancer; 2023 Nov; 129(10):1625-1633. PubMed ID: 37758837
[TBL] [Abstract] [Full Text] [Related]
2. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract] [Full Text] [Related]
3. Metformin Has a Positive Therapeutic Effect on Prostate cancer in Patients With Type 2 Diabetes Mellitus.
Chong RW; Vasudevan V; Zuber J; Solomon SS
Am J Med Sci; 2016 Apr; 351(4):416-9. PubMed ID: 27079349
[TBL] [Abstract] [Full Text] [Related]
4. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
[TBL] [Abstract] [Full Text] [Related]
5. Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer.
Prudnikova TY; Soulitzis N; Kutsenko OS; Mostovich LA; Haraldson K; Ernberg I; Kashuba VI; Spandidos DA; Zabarovsky ER; Grigorieva EV
Cancer Med; 2013 Oct; 2(5):654-61. PubMed ID: 24403231
[TBL] [Abstract] [Full Text] [Related]
6. Mitochondrial haplogroups and polymorphisms reveal no association with sporadic prostate cancer in a southern European population.
Álvarez-Cubero MJ; Saiz Guinaldo M; Martínez-González LJ; Álvarez Merino JC; Cózar Olmo JM; Acosta JA
PLoS One; 2012; 7(7):e41201. PubMed ID: 22815971
[TBL] [Abstract] [Full Text] [Related]
7. [Circulating tumor cells and advanced prostate cancer].
Murez T; Droupy S; Rebillard X; Alix-Panabieres C
Bull Cancer; 2012 Jul; 99 Suppl 1():S4-15. PubMed ID: 22569300
[TBL] [Abstract] [Full Text] [Related]
8. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract] [Full Text] [Related]
9. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract] [Full Text] [Related]
10. "Male lumpectomy": focal therapy for prostate cancer using cryoablation.
Onik G; Vaughan D; Lotenfoe R; Dineen M; Brady J
Urology; 2007 Dec; 70(6 Suppl):16-21. PubMed ID: 18194706
[TBL] [Abstract] [Full Text] [Related]
11. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.
Kirby R
Nat Clin Pract Urol; 2005 Jun; 2(6):304-8. PubMed ID: 16474813
[TBL] [Abstract] [Full Text] [Related]
12. The role of molecular forms of prostate-specific antigen (psa or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Becker C; Noldus J; Diamandis E; Lilja H
Crit Rev Clin Lab Sci; 2001 Oct; 38(5):357-99. PubMed ID: 11720279
[TBL] [Abstract] [Full Text] [Related]
13. Blood-borne cancer cells--quo vadis?
Brandt B; Schmitt H; Feldner JC; Lellé RJ; Semjonow A; Beckmann A
Int J Biol Markers; 2000; 15(1):111-3. PubMed ID: 10763152
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer.
Heyl W; Wolff JM; Biesterfeld S; Schröder W; Zitzelsberger D; Jakse G; Rath W
Anticancer Res; 1999; 19(4A):2563-5. PubMed ID: 10470195
[TBL] [Abstract] [Full Text] [Related]
15. Prostate specific antigen: an opinion on its value to the radiologist.
Clements R
Eur Radiol; 1999; 9(3):529-35. PubMed ID: 10087129
[TBL] [Abstract] [Full Text] [Related]
16. Prostate-specific antigen and new related markers for prostate cancer.
Daher R; Beaini M
Clin Chem Lab Med; 1998 Sep; 36(9):671-81. PubMed ID: 9804390
[TBL] [Abstract] [Full Text] [Related]
